Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma

Anticancer Research

Volumn 19, Issue 2 B, 1999, Pages 1427-1432

  Zhang, Guo Jun ^a   Adachi, Isamu ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cytokine; Interleukin 6; Metastatic breast cancer; Prognosis

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BONE METASTASIS; BRAIN METASTASIS; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MULTIVARIATE ANALYSIS; PLEURA EFFUSION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SOFT TISSUE TUMOR; TUMOR GROWTH;

ADULT; AGED; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-2; INTERLEUKIN-6; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033036097     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer, J Clin Oncol 14: 2197-205, 1996.
2. Roth BJ, Sledge GW, Jr., Williams SD, Meyer SC, Ansari R, Fisher WB: Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the Hoosier Oncology Group, Cancer 68: 248-52, 1991.
3. Meyer JS and Province MA: S-phase fraction and nuclear size in long term prognosis of patients with breast cancer, Cancer 74: 2287-99, 1994.
4. Leivonen M, Krogerus L, Nordling S: DNA analysis in advanced breast cancer, Cancer Detect Prev 18: 87-96, 1994.
5. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabe S, Terada M, Yamamoto H: Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases, Cancer 65: 1794-800, 1990.
6. Tsuda H, Iwaya K, Fukutomi T, Hirohashi S: p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade, Jpn J Cancer Res 84: 394-401, 1993.
7. Champeme MH, Bieche I, Hacene K, Lidereau R: Oncogene amplification per se: an independent prognostic factor in human breast cancer, Mol Carcinog 11: 189-91, 1994.
8. Borsellino N, Belldegrun A, Bonavida B: Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines, Cancer Res 55: 4633-9, 1995.
9. Peller S, Halevy A, Slutzki S, Kopilova Y, Rotter V: p53 mutations in matched primary and metastatic human tumors, Mol Carcinog 13: 166-72, 1995.
10. Winqvist R, Hampton GM, Mannermaa A, Blanco G, Alavaikko M, Kiviniemi H, Taskinen PJ, Evans GA, Wright FA, Newsham I, et al: Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis, Cancer Res 55: 2660-4, 1995.
11. Kuukasjarvi T, Karhu R, Tanner M, Kahkonen M, Schaffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi OP, Isola J: Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer, Cancer Res 57: 1597-604, 1997.
12. Lai LC, Kadory S, Siraj AK, Lennard TW: Oncostatin M, interleukin 2, interleukin 6 and interleukin 8 in breast cyst fluid, Int J Cancer 59: 369-72, 1994.
13. Basolo F, Conaldi PG, Fiore L, Calvo S, Toniolo A: Normal breast epithelial cells produce interleukins 6 and 8 together with tumor-necrosis factor: defective IL6 expression in mammary carcinoma, Int J Cancer 55: 926-30, 1993.
14. Bebok Z, Markus B, Nemeth P: Prognostic relevance of transforming growth factor alpha (TGF-alpha) and tumor necrosis factor alpha (TNF-alpha) detected in breast cancer tissues by immunohistochemistry, Breast Cancer Res Treat 29: 229-35, 1994.
15. Reed MJ, Coldham NG, Patel SR, Ghilchik MW, James VH: Interleukin-1 and interleukin-6 in breast cyst fluid: their role in regulating aromatase activity in breast cancer cells, J Endocrinol 132: R5-8, 1992.
16. Reed MJ, Topping L, Coldham NG, Purohit A, Ghilchik MW, James VH: Control of aromatase activity in breast cancer cells: the role of cytokines and growth factors, J Steroid Biochem Mol Biol 44: 589-96, 1993.
17. Crichton MB, Nichols JE, Zhao Y, Bulun SE, Simpson ER: Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells, Mol Cell Endocrinol 118: 215-20, 1996.
18. Jeoung DI, Tang B, Sonenberg M: Effects of tumor necrosis factor-alpha on antimitogenicity and cell cycle-related proteins in MCF-7 cells, J Biol Chem 270: 18367-73, 1995.
19. Hirano T and Kishimoto T: Interleukin-6: possible implications in human diseases, Ric Clin Lab 19: 1-10, 1989.
20. Strassmann G, Fong M, Kenney JS, Jacob CO: Evidence for the involvement of interleukin 6 in experimental cancer cachexia, J Clin Invest 89: 1681-4, 1992.
21. Strassmann G, Masui Y, Chizzonite R, Fong M: Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor, J Immunol 150: 2341-5, 1993.
22. Scambia G, Testa U, Panici PB, Martucci R, Foti E, Petrini M, Amoroso M, Masciullo V, Peschle C, Mancuso S: Interleukin-6 serum levels in patients with gynecological tumors, Int J Cancer 57: 318-23, 1994.
23. Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S: Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer, Br J Cancer 71: 354-6, 1995.
24. Scott HR, McMillan DC, Crilly A, McArdle CS, Milroy R: The relationship between weight loss and interleukin 6 in non-small-cell lung cancer, Br J Cancer 73: 1560-2, 1996.
25. Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T, Ogura T: Serum levels of interleukin 6 in patients with lung cancer, Br J Cancer 71: 1095-8, 1995.
26. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, et al: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma, Cancer Res 52: 3317-22, 1992.
27. Gallo O, Gori AM, Attanasio M, Martini F, Giusti B, Brunelli T, Gallina E: Interleukin-6 and acute-phase proteins in head and neck cancer, Eur Arch Otorhinolaryngol 252: 159-62, 1995.
28. Cancer IUA TNM classification of malignant tumors, 4 edition, p. 93-99. Berlin Heidelberg New York: Springer, 1987.
29. The Japanese Society: Breast Cancer General Rules for Clinical and Pathological Recording of Breast Cancer, 12 edition, p. 20-21. Tokyo, Japan: Kanehara Shuppan Publishing co., 1996.
30. Kaplan E and Meier P: Nonparametric estimation from incomplete observations, J Am Stat Assoc 58: 457-481, 1958.
31. Cox O: Regression models and life tables, J R Stat Soc Britain 32: 187-220, 1972.
32. Castell JV, Geiger T, V. G, et al: Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat, Eur J Biochem 177: 357-361, 1988.
33. Yanagawa H, Sone S, Munekata M, Atagi S, Nii A, Ogura T: IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2, Clin Exp Immunol 88: 207-12, 1992.
34. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, et al: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas, Nature 332: 83-5, 1988.
35. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T: Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas, FEBS Lett 250: 607-10, 1989.
36. Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Iizuka N, Hazama S, Hirazawa K, Hayashi H, Tangoku A, Hirose K, Ishihara T. Suzuki T: Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma, Cancer Res 56: 2776-80, 1996.
37. Takizawa H, Ohtoshi T, Ohta K, Yamashita N, Hirohata S, Hirai K, Hiramatsu K, Ito K: Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism, Cancer Res 53: 4175-81, 1993.
38. Chen L, Mory Y, Zilberstein A, Revel M: Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2, Proc Natl Acad Sci U S A 85: 8037-41, 1988.
39. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T: IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells, J Immunol 141: 1543-9, 1988.
40. Weber J, Yang JC, Topalian SL, Parkinson DR, Schwartzentruber DS, Ettinghausen SE, Gunn H, Mixon A, Kim H, Cole D, et al: Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies, J Clin Oncol 11: 499-506, 1993.
41. van Gameren MM, Willemse PH, Mulder NH, Limburg PC, Groen HJ, Vellenga E, de Vries EG: Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study, Blood 84: 1434-41, 1994.
42. Weber J, Gunn H, Yang J, Parkinson D, Topalian S, Schwartzentruber D, Ettinghausen S, Levitt D, Rosenberg SA: A phase I trial of intravenous interleukin-6 in patients with advanced cancer, J Immunother Emphasis Tumor Immunol 15: 292-302, 1994.
43. Ravoet C, Greve JD, Vandewoude K, Kerger J, Sculier J-P, Lacor P, Stryckmans P, Piccart M: Tumour stimulating effects of recombinant human interleukin-6, Lancet 344: 1576-1577, 1994.
44. Tanner J and Tosato G: Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice, J Clin Invest 88: 239-47, 1991.
45. Tamm I, Cardinale I, Sehgal PB: Interleukin-6 and 12-O-tetradecanoyl phorbol-13-acetate act synergistically in inducing cell-cell separation and migration of human breast carcinoma cells, Cytokine 3: 212-23, 1991.
46. Castell JV, Gomez-Lechon MJ, David M, Andus T, Geiger T, Trullenque R, Fabra R, Heinrich PC: Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes, FEBS Lett 242: 237-9, 1989.
47. Yokoe T, Iino Y, Takei H, Horiguchi J, Koibuchi Y, Maemura M, Ohwada S, Morishita Y: Changes of cytokines and thyroid function in patients with recurrent breast cancer, Anticancer Res 17: 695-9, 1997.
48. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6, Nature 352: 345-7, 1991.
49. Purohit A, Ghilchik MW, Duncan L, Wang DY, Singh A, Walker MM, Reed MJ: Aromatase activity and interleukin-6 production by normal and malignant breast tissues, J Clin Endocrinol Metab 80: 3052-8, 1995.
50. Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B: Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments, Blood 86: 3123-31, 1995.